A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)

Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leuk Res
Autors principals: Sallman, David A., Komrokji, Rami S., Sweet, Kendra L., Mo, Qianxing, McGraw, Kathy L., Duong, Vu H., Zhang, Ling, Nardelli, Lisa Ann, Padron, Eric, List, Alan F., Lancet, Jeffrey E.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7787349/
https://ncbi.nlm.nih.gov/pubmed/31030089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2019.03.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars